The $120 million, new biologics research facility at the existing Kenilworth site included a 38,000-SF cell culture facility, 64,000-SF of laboratories and administrative offices and 37,000-SF of support space, including MEP equipment rooms. New construction totaled 139,000-SF with full and partial renovations of existing facilities totaling 18,300-SF. The cell culture facility consisted of 38,000-SF of cell culture process facilities and specialty labs that support the upstream and downstream efforts for biologic research. The laboratory portion of the project supported the cell culture discovery efforts. The renovated facilities were occupied during the course of this project, and all efforts revolved around not disrupting existing scientific activities while performing the work at a high rate of speed. The research facility targeted LEED® certification.
Skanska USA Building
Mark segment: Laboratories, Research centers, Scientific facilities
Start date: 2011
Completion date: 2013
Clients: Merck Sharp & Dohme Corp.
Country: United States
Contract value: 120 M USD
Project status: Completed